Short-Course Ruxolitinib Initiated at Neutrophil Engraftment for Prevention of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter, Randomized, Open-Label, Controlled Phase II Trial.
BACKGROUND Acute graft-versus-host disease (aGVHD) remains a leading cause of non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). On the cyclosporine A (CsA)/methotrexate (MTX)/mycophenolate mofetil (MMF) backbone, MMF withdrawal around engraftment creates an immunosuppress...